These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 10428524)
1. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Beardsworth SA; Kearney CE; Purdie DW Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524 [TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157 [TBL] [Abstract][Full Text] [Related]
3. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Reginster JY; Agnusdei D; Gennari C; Kicovic PM Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554 [TBL] [Abstract][Full Text] [Related]
4. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945 [TBL] [Abstract][Full Text] [Related]
5. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Rymer J; Robinson J; Fogelman I Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564 [TBL] [Abstract][Full Text] [Related]
6. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. Gallagher JC; Baylink DJ; Freeman R; McClung M J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531 [TBL] [Abstract][Full Text] [Related]
7. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Prelevic GM; Bartram C; Wood J; Okolo S; Ginsburg J Gynecol Endocrinol; 1996 Dec; 10(6):413-20. PubMed ID: 9032569 [TBL] [Abstract][Full Text] [Related]
9. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347 [TBL] [Abstract][Full Text] [Related]
10. The influence of physical activity on the response of bone mineral density to 5 years tibolone. Brooke-Wavell K; Prelevic GM; Bartram C; Ginsburg J Maturitas; 2000 Jun; 35(3):229-35. PubMed ID: 10936739 [TBL] [Abstract][Full Text] [Related]
11. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286 [TBL] [Abstract][Full Text] [Related]
14. Prevention of early postmenopausal bone loss with cyclical etidronate. Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149 [TBL] [Abstract][Full Text] [Related]
15. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur. Duan Y; Tabensky A; DeLuca V; Seeman E Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739 [TBL] [Abstract][Full Text] [Related]
16. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777 [TBL] [Abstract][Full Text] [Related]
17. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up. Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493 [TBL] [Abstract][Full Text] [Related]
18. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Rymer J; Robinson J; Fogelman I Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219 [TBL] [Abstract][Full Text] [Related]
19. Spine and femur BMD by DXA in patients with varying severity spinal osteoporosis. Ryan PJ; Blake GM; Herd R; Parker J; Fogelman I Calcif Tissue Int; 1993 Apr; 52(4):263-8. PubMed ID: 8467405 [TBL] [Abstract][Full Text] [Related]
20. Role of oral pamidronate in preventing bone loss in postmenopausal women. Lees B; Garland SW; Walton C; Ross D; Whitehead MI; Stevenson JC Osteoporos Int; 1996; 6(6):480-5. PubMed ID: 9116394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]